Reproductive tract Infections

"Reproductive Tract Infections is designed for public health professionals who want to apply epidemiologic methods to the area of reproductive tract infections (RTIs). The document includes an overview of RTIs, epidemiologic models of RTI transmission, indicators used in RTI epidemiology, surveillance of RTIs, framework for strategic planning for control and prevention of RTIs, implications of research and collected data uses, and two case studies."Divya A. Patel, Nancy M. Burnett, Kathryn M. Curtis ; technical editors, Susan Hillis, Polly Marchbanks."June 2003."The United States Agency for International Development (USAID) provided funding for this project through a Participating Agency Service Agreement with CDC (936-3038.01).Also available via the World Wide Web as an Acrobat .pdf file (428 KB, 96 p.).Includes bibliographical references (p. 81-83)

The social construction of lung cancer: an analysis of representations of lung cancer in UK media

Lung cancer is a commonly occurring cancer in the United Kingdom. However, little attention has been directed at understanding meanings in relation to the disease, and how these are socially constructed. This thesis examines representations of lung cancer in media stories to explore how the disease is constructed and with what effects.Drawing on a social constructionist approach, media stories are understood as public places or sites in which meanings about the world are produced and reproduced through language and discourse. Media portrayals of lung cancer are examined for their content and how they may function to construct meanings and knowledge about lung cancer and people who develop the disease. Media portrayals of breast cancer are used to compare and contrast how the two diseases are portrayed in order to identify differences that may have implications for the construction of meanings.The analysis identifies that media stories draw heavily on discourses that associate lung cancer with death and smoking. It is suggested that stories also draw on wider cultural discourses in which health and dying are constructed as moral issues. As a consequence, lung cancer is constructed as a potentially blameworthy death and thereby unworthy of public attention and support. In contrast, media stories about breast cancer draw on discourses that associate the disease with survival and factors that suggest women as ‘at risk’ rather than the cause of the disease. As a consequence, breast cancer is constructed as an indiscriminate threat and, as such, worthy of public attention.The thesis argues that media representations are illustrative of the social processes and conditions involved in the production and sustenance of lung cancer stigma

ETHICAL AND ORGANISATIONAL CONSIDERATIONS IN SCREENING FOR DEMENTIA

The United Kingdom National Screening Committee (UKNSC) defines screening as “the process of identifying individuals who may be at higher risk of a disease or condition amongst large populations of healthy people”. Building on foundations laid by Wilson and Jungner in the landmark paper in 1968, the UKNSC states that “Once identified, those individuals can consider further tests, and healthcare providers can offer them interventions of benefit. A screening programme needs to offer more benefit than harm, at a reasonable cost to the NHS” (gov.uk 2014). We will consider the ethical issues surrounding some of the UK’s screening programmes and other methods used to assess and communicate patients’ risk of disease. We will discuss the appropriateness of candidate dementia biomarkers in order to inform research into developing such a biomarker or series of biomarkers

Outcomes, infectiousness, and transmission dynamics of patients with extensively drug-resistant tuberculosis and home-discharged patients with programmatically incurable tuberculosis: a prospective cohort study.

BACKGROUND: The emergence of programmatically incurable tuberculosis threatens to destabilise control efforts. The aim of this study was to collect prospective patient-level data to inform treatment and containment strategies. METHODS: In a prospective cohort study, 273 South African patients with extensively drug-resistant tuberculosis, or resistance beyond extensively drug-resistant tuberculosis, were followed up over a period of 6 years. Transmission dynamics, infectiousness, and drug susceptibility were analysed in a subset of patients from the Western Cape using whole-genome sequencing (WGS; n=149), a cough aerosol sampling system (CASS; n=26), and phenotypic testing for 18 drugs (n=179). FINDINGS: Between Oct 1, 2008, and Oct 31, 2012, we enrolled and followed up 273 patients for a median of 20·3 months (IQR 9·6-27·8). 203 (74%) had programmatically incurable tuberculosis and unfavourable outcomes (treatment failure, relapse, default, or death despite treatment with a regimen based on capreomycin, aminosalicylic acid, or both). 172 (63%) patients were discharged home, of whom 104 (60%) had an unfavourable outcome. 54 (31%) home-discharged patients had failed treatment, with a median time to death after discharge of 9·9 months (IQR 4·2-17·4). 35 (20%) home-discharged cases were smear-positive at discharge. Using CASS, six (23%) of 26 home-discharged cases with data available expectorated infectious culture-positive cough aerosols in the respirable range (<5 μm), and most reported inter-person contact with suboptimal protective mask usage. WGS identified 17 (19%) of the 90 patients (with available sequence data) that were discharged home before the diagnosis of 20 downstream cases of extensively drug-resistant tuberculosis with almost identical sequencing profiles suggestive of community-based transmission (five or fewer single nucleotide polymorphisms different and with identical resistance-encoding mutations for 14 drugs). 11 (55%) of these downstream cases had HIV co-infection and ten (50%) had died by the end of the study. 22 (56%) of 39 isolates in patients discharged home after treatment failure were resistant to eight or more drugs. However, five (16%) of 31 isolates were susceptible to rifabutin and more than 90% were likely to be sensitive to linezolid, bedaquiline, and delamanid. INTERPRETATION: More than half of the patients with programmatically incurable tuberculosis were discharged into the community where they remained for an average of 16 months, were at risk of expectorating infectious cough aerosols, and posed a threat of transmission of extensively drug-resistant tuberculosis. Urgent action, including appropriate containment strategies, is needed to address this situation. Access to delamanid, bedaquiline, linezolid, and rifabutin, when appropriate, must be accelerated along with comprehensive drug susceptibility testing. FUNDING: UK Medical Research Council, South African Medical Research Council, South African National Research Foundation, European & Developing Countries Clinical Trials Partnership, Oppenheimer Foundation, Newton Fund, Biotechnology and Biological Sciences Research Council, King Abdullah University of Science & Technology

ETHICAL AND ORGANISATIONAL CONSIDERATIONS IN SCREENING FOR DEMENTIA

The United Kingdom National Screening Committee (UKNSC) defines screening as “the process of identifying individuals who may be at higher risk of a disease or condition amongst large populations of healthy people”. Building on foundations laid by Wilson and Jungner in the landmark paper in 1968, the UKNSC states that “Once identified, those individuals can consider further tests, and healthcare providers can offer them interventions of benefit. A screening programme needs to offer more benefit than harm, at a reasonable cost to the NHS” (gov.uk 2014). We will consider the ethical issues surrounding some of the UK’s screening programmes and other methods used to assess and communicate patients’ risk of disease. We will discuss the appropriateness of candidate dementia biomarkers in order to inform research into developing such a biomarker or series of biomarkers

Surgery Triggers Outgrowth of Latent Distant Disease in Breast Cancer: An Inconvenient Truth?

We review our work over the past 14 years that began when we were first confronted with bimodal relapse patterns in two breast cancer databases from different countries. These data were unexplainable with the accepted continuous tumor growth paradigm. To explain these data, we proposed that metastatic breast cancer growth commonly includes periods of temporary dormancy at both the single cell phase and the avascular micrometastasis phase. We also suggested that surgery to remove the primary tumor often terminates dormancy resulting in accelerated relapses. These iatrogenic events are apparently very common in that over half of all metastatic relapses progress in that manner. Assuming this is true, there should be ample and clear evidence in clinical data. We review here the breast cancer paradigm from a variety of historical, clinical, and scientific perspectives and consider how dormancy and surgery-driven escape from dormancy would be observed and what this would mean. Dormancy can be identified in these diverse data but most conspicuous is the sudden synchronized escape from dormancy following primary surgery. On the basis of our findings, we suggest a new paradigm for early stage breast cancer. We also suggest a new treatment that is meant to stabilize and preserve dormancy rather than attempt to kill all cancer cells as is the present strategy

The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis.

Global tuberculosis incidence has declined marginally over the past decade, and tuberculosis remains out of control in several parts of the world including Africa and Asia. Although tuberculosis control has been effective in some regions of the world, these gains are threatened by the increasing burden of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis. XDR tuberculosis has evolved in several tuberculosis-endemic countries to drug-incurable or programmatically incurable tuberculosis (totally drug-resistant tuberculosis). This poses several challenges similar to those encountered in the pre-chemotherapy era, including the inability to cure tuberculosis, high mortality, and the need for alternative methods to prevent disease transmission. This phenomenon mirrors the worldwide increase in antimicrobial resistance and the emergence of other MDR pathogens, such as malaria, HIV, and Gram-negative bacteria. MDR and XDR tuberculosis are associated with high morbidity and substantial mortality, are a threat to health-care workers, prohibitively expensive to treat, and are therefore a serious public health problem. In this Commission, we examine several aspects of drug-resistant tuberculosis. The traditional view that acquired resistance to antituberculous drugs is driven by poor compliance and programmatic failure is now being questioned, and several lines of evidence suggest that alternative mechanisms-including pharmacokinetic variability, induction of efflux pumps that transport the drug out of cells, and suboptimal drug penetration into tuberculosis lesions-are likely crucial to the pathogenesis of drug-resistant tuberculosis. These factors have implications for the design of new interventions, drug delivery and dosing mechanisms, and public health policy. We discuss epidemiology and transmission dynamics, including new insights into the fundamental biology of transmission, and we review the utility of newer diagnostic tools, including molecular tests and next-generation whole-genome sequencing, and their potential for clinical effectiveness. Relevant research priorities are highlighted, including optimal medical and surgical management, the role of newer and repurposed drugs (including bedaquiline, delamanid, and linezolid), pharmacokinetic and pharmacodynamic considerations, preventive strategies (such as prophylaxis in MDR and XDR contacts), palliative and patient-orientated care aspects, and medicolegal and ethical issues